{
  "analyses": [
    {
      "symbol": "INCY",
      "approved": true,
      "consensus_score": 7.03,
      "agent_scores": {
        "fundamental": 7.5,
        "technical": 6.8,
        "news": 8.0,
        "sentiment": 7,
        "bull": 7.8,
        "bear": 5,
        "risk": 7
      },
      "position_size_pct": 5,
      "position_size_shares": 61,
      "current_price": 84.78,
      "stop_price": 78.0,
      "target_price": 92.0,
      "catalyst": "Sept 19 FDA decision (PDUFA) - Opzelura pediatric approval"
    },
    {
      "symbol": "SRRK",
      "approved": true,
      "consensus_score": 7.03,
      "agent_scores": {
        "fundamental": 7.5,
        "technical": 6.8,
        "news": 8.0,
        "sentiment": 7,
        "bull": 7.8,
        "bear": 5,
        "risk": 7
      },
      "position_size_pct": 3,
      "position_size_shares": 97,
      "current_price": 32.0,
      "stop_price": 29.44,
      "target_price": 40.0,
      "catalyst": "Sept 22 FDA decision - apitegromab (SMA drug)"
    },
    {
      "symbol": "FBIO",
      "approved": true,
      "consensus_score": 7.03,
      "agent_scores": {
        "fundamental": 7.5,
        "technical": 6.8,
        "news": 8.0,
        "sentiment": 7,
        "bull": 7.8,
        "bear": 5,
        "risk": 7
      },
      "position_size_pct": 2,
      "position_size_shares": 608,
      "current_price": 3.4,
      "stop_price": 3.13,
      "target_price": 3.0,
      "catalyst": "Sept 30 FDA decision - rare disease drug, PRV potential"
    },
    {
      "symbol": "RIVN",
      "approved": true,
      "consensus_score": 7.03,
      "agent_scores": {
        "fundamental": 7.5,
        "technical": 6.8,
        "news": 8.0,
        "sentiment": 7,
        "bull": 7.8,
        "bear": 5,
        "risk": 7
      },
      "position_size_pct": 6,
      "position_size_shares": 440,
      "current_price": 14.1,
      "stop_price": 12.97,
      "target_price": 16.0,
      "catalyst": "Early Oct deliveries report; R2 model updates"
    },
    {
      "symbol": "HELE",
      "approved": true,
      "consensus_score": 7.03,
      "agent_scores": {
        "fundamental": 7.5,
        "technical": 6.8,
        "news": 8.0,
        "sentiment": 7,
        "bull": 7.8,
        "bear": 5,
        "risk": 7
      },
      "position_size_pct": 4,
      "position_size_shares": 180,
      "current_price": 22.91,
      "stop_price": 21.08,
      "target_price": 28.0,
      "catalyst": "Ongoing - New CEO + insider buys; turnaround progress"
    }
  ],
  "executed": [],
  "rejected": [
    "INCY",
    "SRRK",
    "FBIO",
    "RIVN",
    "HELE"
  ]
}